Hill-Rom Holdings Inc., of Chicago, has inked an agreement to acquire Sarasota, Fla.-based Voalte Inc., which focuses on real-time, mobile health care communications, for an initial $180 million and up to an additional $15 million in payments related to the achievement of certain commercial milestones.

Pancreatic cancer patients face tough odds, given that the disease has a five-year survival rate of less than 9 percent. Now, researchers at the University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh School of Medicine have reported the publication of a study in pancreatic ductal adenocarcinomas (PDAC) that looked into the role of comprehensive genomic profiling in treatment and clinical research. The study characterized the genome of 3,594 pancreatic tumor samples from patients around the world, provided by collaborators at Cambridge, Mass.-based Foundation Medicine Inc.

Neuronetics Inc. reported solid results for its fourth quarter, seeing revenue for its Neurostar Advanced Therapy come in at $4.8 million. That represented an increase of 37 percent vs. the prior year's figure of $3.5 million.

Pacira Pharmaceuticals Inc., of Parsippany, N.J., said it will scoop up Fremont, Calif.-based Myoscience Inc., which markets the Iovera system as a nonopioid treatment that alleviates pain through cryoanalgesia. Pacira will make an initial payment of $120 million, and Myoscience will be eligible to receive up to an additional $100 million upon achievement of certain regulatory and commercial milestones.

Pacira Pharmaceuticals Inc., of Parsippany, N.J., said it will scoop up Fremont, Calif.-based Myoscience Inc., which markets the Iovera system as a non-opioid treatment that alleviates pain through cryoanalgesia. Pacira will make an initial payment of $120 million, and Myoscience will be eligible to receive up to an additional $100 million upon achievement of certain regulatory and commercial milestones.

Lexington, Mass.-based T2 Biosystems Inc. won breakthrough device designation for the T2resistance panel, which can detect 13 resistance genes from both gram-positive and gram-negative pathogens. Of note, it can detect those pathogens from a single patient blood sample, without the wait for a blood culture.

Centogene AG is teaming up with Sarepta Therapeutics Inc., of Cambridge, Mass., to identify patients with Duchenne muscular dystrophy (DMD) in the Middle East and North Africa region. As part of the collaboration, Rostock, Germany-based Centogene will perform complete molecular diagnostic testing, as well as provide diagnostic services to physicians treating patients exhibiting symptoms related to DMD.